Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
BioPharma DiveJonathan GardnerNovember 16, 2026
The FDA refused to overlook ivonescimab s failure to initially extend survival in a form of lung cancer, setting back Summit s first chance to win a U.S. approval.
